[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-343199-105":59,"doc-detail-343199-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","comprehensive-serum-glycopeptide-spectra-analysis-to-identify-early-stage-epithelial-ovarian-cancer","Comprehensive serum glycopeptide spectra analysis to identify early-stage epithelial ovarian cancer","","Epithelial ovarian cancer remains a major clinical challenge because early-stage detection is difficult and many patients present after progression. A new diagnostic framework, Comprehensive Serum Glycopeptide Spectral Analysis (CSGSA), integrates glycan alterations in serum glycoproteins with tumor markers. The study identified 1,712 glycopeptides via liquid chromatography–mass spectrometry from sera of 564 EOC patients and 1,149 controls across 13 institutions. A convolutional neural network achieved strong discrimination of Stage I EOC from non-EOC (ROC-AUC 0.924), outperforming CA125 and HE4, and showed effective separation of clear cell carcinoma from endometrioma.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/comprehensive-serum-glycopeptide-spectra-analysis-to-identify-early-stage-epithelial-ovarian-cancer/343199/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/comprehensive-serum-glycopeptide-spectra-analysis-to-identify-early-stage-epithelial-ovarian-cancer/343199.png","ImageObject",300,407,{"name":92,"@type":93},"Levi","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What problem does the CSGSA method target in epithelial ovarian cancer care?","Question",{"text":112,"@type":113},"It targets the clinical difficulty of detecting early-stage epithelial ovarian cancer, which is often asymptomatic and therefore diagnosed late.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does CSGSA work, and what data does it use?",{"text":117,"@type":113},"CSGSA combines glycan alterations in serum glycoproteins with tumor marker information, using liquid chromatography–mass spectrometry to identify glycopeptides and a convolutional neural network to analyze expression patterns.",{"name":119,"@type":110,"acceptedAnswer":120},"How does the method perform compared with conventional tumor markers like CA125 and HE4?",{"text":121,"@type":113},"For early-stage (Stage I) EOC versus non-EOC, the approach achieved ROC-AUC 0.924, outperforming CA125 (0.842) and HE4 (0.717). It also differentiated ovarian clear cell carcinoma from endometrioma with ROC-AUC 0.808, exceeding CA125 and HE4 in that setting.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},343199,1790193941,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":36,"preview_page_count":19,"preview_urls":145},7971461740909,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nComprehensive serum glycopeptide spectra analysis to identify early‑stage epithelial ovarian cancer  \nMikio Mikami1,16*, Kazuhiro Tanabe2,16*, Tadashi Imanishi3,4,5, Masae Ikeda1,  \nTakeshi Hirasawa1, Miwa Yasaka1, Hiroko Machida1, Hiroshi Yoshida1, Masanori Hasegawa6, Muneaki Shimada7, Tomoyasu Kato8, Shoichi Kitamura8, Hisamori Kato9, Takuma Fujii10, Yoichi Kobayashi11, Nao Suzuki12, Kyoko Tanaka13, Isao Murakami13, Tomoko Katahira2, Chihiro Hayashi2 & Koji Matsuo14,15  \nEpithelial ovarian cancer (EOC) is widely recognized as the most lethal gynecological malignancy; however, its early‑stage detection remains a considerable clinical challenge. To address this, we have introduced a new method, named Comprehensive Serum Glycopeptide Spectral Analysis (CSGSA), which detects early‑stage cancer by combining glycan alterations in serum glycoproteins with tumor markers. We detected 1712 glycopeptides using liquid chromatography–mass spectrometry from the sera obtained from 564 patients with EOC and 1149 controls across 13 institutions. Furthermore, we used a convolutional neural network to analyze the expression patterns of the glycopeptides and tumor markers. Using this approach, we successfully differentiated early‑stage EOC (Stage I) from non‑EOC, with an area under the curve (AUC) of 0.924 in receiver operating characteristic (ROC) analysis. This method markedly outperforms conventional tumor markers, including cancer antigen 125 (CA125, 0.842) and human epididymis protein 4 (HE4, 0.717) . Notably, our method exhibited remarkable efficacy in differentiating early‑stage ovarian clear cell carcinoma from endometrioma, achieving a ROC‑AUC of 0.808, outperforming CA125 (0.538) and HE4 (0.557). Our study presents a promising breakthrough in the early detection of EOC through the innovative CSGSA method. The integration of glycan alterations with cancer‑related tumor markers has demonstrated exceptional diagnostic potential.  \nKeywords Ovarian cancer, Clear cell carcinoma, Convolutional neural network, Glycopeptide, Mass spectrometry, Glycomics  \n1Department of Obstetrics and Gynecology, Tokai University School of Medicine, Isehara, Kanagawa, Japan. 2Medical Solution Promotion Department, Medical Solution Segment, LSI Medience Corporation, Itabashi-ku, Tokyo, Japan. 3Genome Diversity Research Center, Graduate School of Medicine, Tokai University, Isehara, Kanagawa, Japan. 4Department of Molecular Life Science, Tokai University School of Medicine, Isehara, Kanagawa, Japan. 5Institute of Medical Sciences, Tokai University, Isehara, Kanagawa, Japan. 6Department of Urology, Tokai University School of Medicine, Isehara, Kanagawa, Japan. 7Department of Obstetrics and Gynecology, Tohoku University School of Medicine, Sendai, Miyagi, Japan. 8Department of Gynecology, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan. 9Department of Gynecologic Oncology, Kanagawa Cancer Center, Yokohama, Kanagawa, Japan. 10Department of Obstetrics and Gynecology, Fujita Health University School of Medicine, Toyoake, Aichi, Japan. 11Department of Obstetrics and Gynecology, Faculty of Medicine, Kyorin University, Mitaka, Tokyo, Japan. 12Department of Obstetrics and Gynecology, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan. 13Department of Obstetrics and Gynecology, Toho University Ohashi Medical Center, Meguro-ku, Tokyo, Japan. 14Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Southern California, Los Angeles, CA, USA. 15Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA. 16These authors contributed equally to this work: Mikio  \nMikami and Kazuhiro Tanabe.*[email: mmikami@tokai.ac.jp](email: mmikami@tokai.ac.jp); [kazuhirotanabe77@gmail.com](kazuhirotanabe77@gmail.com)  \n[www. nature.com/scientificreports/](www. nature.com/scientificreports/)  \nAbbreviations  \nEOC  \nCCC  \nC","cbCaies2sItapjK4","https://ap.wps.com/l/cbCaies2sItapjK4","pdf",4887903,16,"English","# Abstract\n## Background and clinical need\n## Proposed method (CSGSA) and study design\n## Diagnostic performance versus conventional markers\n## Rationale and prior biomarker approaches\n## Scope of epithelial ovarian cancer subtypes","[{\"question\":\"What problem does the CSGSA method target in epithelial ovarian cancer care?\",\"answer\":\"It targets the clinical difficulty of detecting early-stage epithelial ovarian cancer, which is often asymptomatic and therefore diagnosed late.\"},{\"question\":\"How does CSGSA work, and what data does it use?\",\"answer\":\"CSGSA combines glycan alterations in serum glycoproteins with tumor marker information, using liquid chromatography–mass spectrometry to identify glycopeptides and a convolutional neural network to analyze expression patterns.\"},{\"question\":\"How does the method perform compared with conventional tumor markers like CA125 and HE4?\",\"answer\":\"For early-stage (Stage I) EOC versus non-EOC, the approach achieved ROC-AUC 0.924, outperforming CA125 (0.842) and HE4 (0.717). It also differentiated ovarian clear cell carcinoma from endometrioma with ROC-AUC 0.808, exceeding CA125 and HE4 in that setting.\"}]","Comprehensive serum glycopeptide spectra analysis to identify early-stage epithelial ovarian cancer | PDF",1790050253,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/481c01c3e68504ac09df6910d9c5d321.webp",983,1291,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/77e7531acbcc5db499a13614db8991ff.webp",982,1290,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/347c74da7cd7fb73d43bfd773363e74b.webp",981,1289,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b28643c0cf19a3fa54d9699692c3194e.webp",980,1287]